J&J builds case for antidepressant Spravato with head-to-head trial
pharmaphorum
NOVEMBER 24, 2022
Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide. Both drugs were given on top of standard antidepressants to patients wo had failed a least two earlier treatments.
52 
Let's personalize your content